$LRMR News
Last published 2d ago
- 2d agoLRMRLarimar Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 2d agoLRMRLarimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s AtaxiaGlobeNewswireCompleted BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FASubmission follows FDA alignment on key elements of the BLA
- 6d agoLRMRLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia ResearchGlobeNewswireBALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
- 6d agoLRMRLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia ResearchGlobeNewswireBALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 1w agoLRMRLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireBALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2mo agoIPSCLRMRCentury Therapeutics Appoints Joseph Truitt to Board of DirectorsGlobeNewswirePHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 3mo agoLRMRLarimar Therapeutics Reports Second Quarter 2026 Financial and Business UpdateGlobeNewswirePositive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome
- 4mo agoLRMRLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s AtaxiaGlobeNewswireFDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026Daily nomlabofusp increased and
- 4mo agoLRMRLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s AtaxiaGlobeNewswireWebcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing
- 6mo agoLRMRLarimar Therapeutics Reports First Quarter 2026 Financial and Business UpdateGlobeNewswireIntending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of
- 6mo agoLRMRLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaGlobeNewswireBALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 8mo agoLRMRLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchGlobeNewswireBALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 8mo agoLRMRLarimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingGlobeNewswireBALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 8mo agoLRMRLarimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingGlobeNewswireBALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 8mo agoKBLBLRMRMETAVIRBiotech and Big Tech Drive the Morning NarrativeGlobeNewswireDENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to
- 8mo agoLRMRLarimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026GlobeNewswireNomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyFDA written communications after recent
- 10mo agoLRMRLarimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced
- 1y agoLRMRLarimar Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswireIn the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriersConsistent directional improvement across mFARS,
- 1y agoLRMRLarimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's AtaxiaGlobeNewswireIn 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study
- 1y agoLRMRLarimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's AtaxiaGlobeNewswireBALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc.
- 1y agoLRMRLarimar Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswireInitial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients with FA who have not
- 1y agoLRMRLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewswireBALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 1y agoLRMRLarimar Therapeutics Announces Pricing of Underwritten Public OfferingGlobeNewswireBALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 1y agoLRMRLarimar Therapeutics Announces Proposed Underwritten Public OfferingGlobeNewswireBALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 1y agoLRMRLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's AtaxiaGlobeNewswireBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced
- 1y agoLRMRLarimar Therapeutics Reports First Quarter 2025 Financial ResultsGlobeNewswireFDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval
- 1y agoLRMRLarimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireFDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended
- 1y agoLRMRLarimar Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireBALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 1y agoLRMRLarimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's AtaxiaGlobeNewswireAdolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open
- 1y agoLRMRLarimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's AtaxiaGlobeNewswireDaily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from
- 1y agoLRMRLarimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024GlobeNewswireTreatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with Friedreich's ataxia (FA)Modeling and simulation predict that, in most
- 2y agoLRMRLarimar Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsGlobeNewswireNomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich's ataxia (FA)
- 2y agoLRMRLarimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia ResearchGlobeNewswireBALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2y agoLRMRLarimar Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced
- 2y agoLRMRLarimar Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsGlobeNewswireOpen label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare
- 2y agoLRMRLarimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's AtaxiaGlobeNewswireSTART is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for clinical benefit in
- 2y agoLRMRLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's AtaxiaGlobeNewswireFood and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose escalate
- 2y agoLRMRLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsGlobeNewswireFirst patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was
- 2y agoLRMRLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentGlobeNewswirePositive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observedInitiated discussions with the Food and Drug
- 2y agoLRMRLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaGlobeNewswireStudy will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help support
- 2y agoLRMRLarimar Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceGlobeNewswireBALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2y agoLRMRLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewswireBALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2y agoLRMRLarimar Therapeutics Announces Pricing of Underwritten Public Offering of Common StockGlobeNewswireBALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2y agoLRMRLarimar Therapeutics Announces Proposed Underwritten Public OfferingGlobeNewswireBALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 2y agoLRMRLarimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's AtaxiaGlobeNewswireNomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse eventsDose dependent increases in frataxin levels were observed in skin
- 2y agoLRMRLarimar Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsGlobeNewswireCompleted full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in
- 3y agoLRMRLarimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology ConferenceGlobeNewswireBALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 3y agoLRMRLarimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of DirectorsGlobeNewswireBALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 3y agoLRMRLarimar Therapeutics to Present at the Citi 18th Annual BioPharma ConferenceGlobeNewswireBALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today
- 3y agoLRMRLarimar Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsGlobeNewswireInitiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial